Not everyone who contracts the Ebola virus dies, the survival rate is around 30% suggesting that some kind of immunity to the disease is possible. Experimental treatments and vaccines against Ebola exist but have not yet been tested in large groups for safety and efficacy (phase 2 trials).
The International Union of Immunology Societies (IUIS) published a statement today in its official journal, Frontiers in Immunology calling for urgent and adequate funding of vaccine candidates in clinical trials and speedy implementation of immunisation in African countries.
Page 2370 of 2411
ENN Daily Newsletter
ENN Weekly Newsletter